| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ANTX | Common Stock | Sale | -$11.4K | -707 | -0.03% | $16.07 | 2.18M | Sep 27, 2023 | By Adjuvant Global Health Technology Fund, L.P. | F1, F2, F3 |
| transaction | ANTX | Common Stock | Sale | -$2.15K | -134 | -0.03% | $16.07 | 412K | Sep 27, 2023 | By Adjuvant Global Health Technology Fund DE, L.P. | F1, F2, F4 |
| transaction | ANTX | Common Stock | Sale | -$115K | -7.16K | -0.33% | $16.11 | 2.17M | Sep 28, 2023 | By Adjuvant Global Health Technology Fund, L.P.( | F1, F3, F5 |
| transaction | ANTX | Common Stock | Sale | -$21.8K | -1.36K | -0.33% | $16.11 | 410K | Sep 28, 2023 | By Adjuvant Global Health Technology Fund DE, L.P | F1, F4, F5 |
| Id | Content |
|---|---|
| F1 | The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2022. |
| F2 | The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.14, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | Shares held directly by Adjuvant Global Health Technology Fund, L.P. ("AGHT Fund"). The sole general partner of AGHT Fund is Adjuvant Capital GP, L.P. ("AC GP") and the sole general partner of AC GP is Adjuvant Capital Management, L.L.C. ("AC MGMT"). The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. |
| F4 | Shares held directly by Adjuvant Global Health Technology Fund DE, L.P. ("AGHT Fund DE"). The sole general partner of AGHT Fund DE is AC GP and the sole general partner of AC GP is AC MGMT. The Reporting Person is a member of the Issuer's board of directors and is Secretary of AC MGMT, and may be deemed to share voting and dispositive power over the securities held by such entities. Each such person and entity disclaims beneficial ownership of the securities, except to the extent of such person's or entity's pecuniary interest in such securities. |
| F5 | The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $16.00 to $16.57, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |